Praxis Precision Medicines Inc Stock News

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on November 3, 2025, the Compensation Committee of Praxis' Board of Directors...

The volatile sector is seeing greater stability, and these four stocks can profit.

Shares of Praxis Precision Medicine shot 251% higher in a little over a week during the month of October. Praxis Precision Medicine announced successful results from a phase 3 trial with its lead candidate.

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,025,480 shares of its common ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX ) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program October 16, 2025 8:00 AM EDT Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Daniel Ferry - Lifesci Advisors, LLC Ritu Baral - TD Cowen, Research Division Yasmeen Rahimi - Piper Sandler & Co., Research Division Joon Lee - Trui...

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced a proposed public offering of its common stock and, in lieu of common stock to cer...

Shares of Praxis Precision Medicines have hit their highest intraday level since March 2022.

Praxis Precision Medicines (NASDAQ: PRAX stock) saw a skyrocketing 235% rally on Thursday after announcing positive topline results from two pivotal Phase 3 studies of ulixacaltamide for essential tremor, a common movement disorder.